Sign up
Pharma Capital

Avita Medical pauses trading to make arrangements

The halt will remain in place until Wednesday 11th October 2017.
1507504024_ASX2.jpg
The company's shares are in pre-open

Avita Medical Ltd (ASX:AVH) has been granted a trading halt by the ASX this morning to allow the company to make arrangements surrounding a potential capital raising

Shares in the company last traded at $0.085, or around 45% higher than two weeks earlier.

The positive re-rating came after the U.S. Food & Drug Administration (FDA) has approved a supplement to the company’s Investigational Device Exemption for its ReCell® Autologous Cell Harvesting Device.

Avita's treatments are focused on the regenerative properties of a patient’s own skin.

The halt will remain in place until the opening of trade on Wednesday 11th October 2017, or earlier if an announcement is made to the market.

View full AVH profile

Avita Medical Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.